Dupont Capital Management Corp Mirati Therapeutics, Inc. Transaction History

Dupont Capital Management Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 26, 2023	BUY	$41.27 - $98.62 $78,784 - $188,265	1,909 New	1,909 $0
Q1 2022 Apr 27, 2022	SELL	$75.82 - $150.97 $58,836 - $117,152	-776 Closed	0 $0
Q4 2021 Jan 31, 2022	BUY	$132.01 - $190.29 $102,439 - $147,665	776 New	776 $114,000
Q4 2020 Jan 28, 2021	SELL	$162.05 - $240.27 $497,493 - $737,628	-3,070 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$113.26 - $167.27 $347,708 - $513,518	3,070 New	3,070 $510,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.